SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Acquisition

1 Sep 2015 07:03

RNS Number : 5824X
Rentokil Initial PLC
01 September 2015
 



 

1 September 2015

ACQUISITION OF STERITECH GROUP INC.

Catalyst for driving accelerated growth and significantly enhanced margins in North America

 

Rentokil Initial plc (FTSE: RTO, "the Company") today announces the agreement to acquire The Steritech Group, Inc. ("Steritech") - one of the leading pest control businesses in North America, operating in both the United States of America and Canada - further accelerating the growth of its pest control business.

Highlights

· The Company has agreed to acquire Steritech for $425m in cash, subject to US regulatory approval.

· Steritech is a high quality provider of pest control services with a US national footprint. It is also the market leading provider of brand standards auditing services in North America.

· The acquisition strengthens our position as the number three pest control business in the US, a c$7.5bn market which accounts for c50% of global pest control services and is a key strategic market in our Growth quadrant.

· Rentokil also becomes the third largest pest control company in Canada, creating a competitive national business, twice the size of its current Canadian operations.

· The Company's North American business now has annual revenues of c$0.8bn and becomes its largest operation.

· Steritech provides a highly complementary geographic fit - building route density and scale in line with the Company's strategy for profitable growth.

· The brand standards auditing business provides a new dimension to Rentokil Initial's pest and hygiene services with potential for global leverage.

· Steritech has a well-deserved reputation for market leading quality standards and technical know-how. The Company sees a strong cultural fit with emphasis on customer care as evidenced by high levels of customer retention.

· Strong financial case based on year three cost synergies estimated to be at least $25m and good revenue synergies.

· The transaction is expected to deliver profit before interest, tax and amortisation ("EBITA"1) of $25m - $30m in 2016 and to achieve EBITA returns in excess of 12% by 2018.

Andy Ransom, Chief Executive of Rentokil Initial plc, commented: "For some time we have been pursuing a growth strategy in North America, the world's largest pest control market, with Steritech at the top of our target list. It has an outstanding management team with a proven track record and a reputation founded on technical expertise and a premium service, similar to ours. It is also highly geographically complementary to our existing US business.

"This is a rare opportunity to acquire a high-quality business with national scale in this key target growth market. The deal is in line with our growth strategy and will be transformational for Rentokil in North America, providing us with the opportunity to further accelerate our revenue growth and significantly enhance margins."

Rich Ennis, CEO of Steritech, commented: "Steritech's success has largely been based on great people delivering world class service to customers. Rentokil's strong culture and focus on people make them the perfect fit for Steritech's people and customers. I believe that the future is bright for the new organization."

Steritech Overview

Steritech, which is headquartered in Charlotte, North Carolina, was established in 1986 and is one of the leading pest control businesses in North America. Steritech is engaged in commercial pest control (approximately $97m of revenue) and brand standards auditing (approximately $53m). It has a high quality management team with particular strengths in national and large account sales. We plan to retain all key Steritech management in the combined business.

In addition to its core pest control operations, Steritech is North America's market leader for brand standards auditing to the restaurant and food retail industries. This service is delivered through onsite audits covering food safety, operational excellence and quality of customer service. 

Brand standards auditing is an attractive additional business line which has similar customer segments to pest control. These services are delivered by highly trained consultant auditors who help customers to deliver consistently on their brand promises by providing a third party monitoring mechanism. This evaluates whether their food preparation, food delivery and customer experience criteria are being met. Further, these audits identify where corrective action is required. The brand standards business has grown organically by a compound annual growth rate ("CAGR") of c14% since 2013. Rentokil does not currently service this market (currently worth $325m p.a. in North America), and so the acquisition of Steritech provides the Company with access to a relatively under-developed market with high growth potential both in North America and eventually internationally through leverage of Steritech's North American relationships and Rentokil's international footprint.

The brand standards and pest control businesses are highly complementary providing significant opportunities for increased lead generation across the combined business.

Financial Performance

Steritech has a strong track record of revenue growth and customer retention with revenues growing by a CAGR of 10% since 2013.

Steritech's reported EBITA in the year ended March 2015 was c$10m. Based on pro forma adjustments the Company estimates underlying2 EBITA for the year ended March 2015 to be c$15m. Rentokil expects to be able to increase EBITA to over $50m by 2018 through cost synergies of at least $25m including back office and operational cost savings across Rentokil Initial's combined North American business with the remainder of profit growth through revenue growth and synergies. Steritech operates on an "asset-light" basis with gross assets at 31 March 2015 amounting to c$38m.

Significant Opportunity to Accelerate Growth and Margins

Rentokil Initial has been pursuing a strategy of growth in the highly attractive North American pest control market for several years. The Company's pest control business in North America has grown by a CAGR of c15% since 2006 through both strong organic growth and acquisitions. The acquisition of Steritech provides an excellent opportunity for accelerated revenue growth in our North American business organically and through synergies including national accounts sales, increased jobbing work and the provision of new services to existing customers.

The acquisition increases our scale in North America, creating a business which, combined with the recent acquisition of Anderson Pest Solutions in Chicago (announced on 28 August 2015), now has annual revenues of c$0.8bn. This will help the Company in its ambition to achieve significantly enhanced margins through leverage of head office costs, reductions in branch level operational administration, better procurement terms, increased route density, improved service technician productivity and field management span of control. The strong geographical fit enables the Company to infill existing low density states in North Carolina and South Carolina, as well as build density in the West, Midwest and Northeast.

Transaction Overview

The transaction will be financed through existing cash resources and a new debt facility which provides the Company with the opportunity to borrow up to £300m, maturing in 2018, at an interest rate of c1.5%, resulting in interest costs relating to this transaction of c£4m in 2016. The transaction is expected to close in the fourth quarter of 2015 upon satisfaction of certain customary conditions, including Hart-Scott-Rodino anti-trust clearance.

1 EBITA has been calculated before transaction costs and one-off integration costs.

2 Underlying EBITA has been calculated after adjusting for the impact of non-recurring or non-operating items including one-off IT costs, non-cash write-offs and ownership costs.

--ENDS--

 

Conference call for investors and analysts

 

A conference call for investors and analysts will be held at 0830hrs (BST-UK) on Tuesday 1 September 2015.

 

Participant Access telephone numbers

 

UK:

+44(0)20 3427 1905

France:

+33(0)1 76 77 22 26

Hong Kong:

+852 3068 9885

USA:

+1 212 444 0895

Participant PIN code: 4437876#

Playback Details (available for 14 days):

UK:

+44(0)203 427 0598

France:

+33(0)1 74 20 28 00

Hong Kong:

+852 3011 4669

USA:

+1 347 366 9565

Playback PIN code: 4437876#

 

Enquiries:

 

Investor / Analyst enquiries:

Katharine Rycroft, Investor Relations, Rentokil Initial plc

07811 270 734

Media enquiries:

Malcolm Padley, Corporate Communications, Rentokil Initial plc

07788 978 199

Ben Woodford, Bell Pottinger

0203 772 2549

 

 

Notes to Editors:

 

About Rentokil Initial plc

Rentokil Initial is one of the largest business services companies in the world, operating in over 60 countries. The Company offers route-based services including Pest Control, Hygiene and Workwear through teams of local experts.

In the first six months of 2015, the North American Region delivered revenue +8.3%, with strong profit growth of +19.5% driven by acquisitions and leverage impact from higher revenues.

www.rentokil-initial.com 

www.steritech.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQUARRRVRAWOUR
Date   Source Headline
29th Aug 20187:00 amRNSDirector/PDMR Shareholding
20th Aug 201812:44 pmRNSDirector/PDMR Shareholding
1st Aug 20183:12 pmRNSHolding(s) in Company
31st Jul 20187:00 amRNSInterim Results
27th Jul 20185:07 pmRNSHolding(s) in Company
5th Jul 20184:52 pmRNSHolding(s) in Company
5th Jul 201811:36 amRNSDirector Declaration
28th Jun 20184:10 pmRNSHolding(s) in Company
7th Jun 20185:16 pmRNSDirector Declaration
17th May 20184:12 pmRNSDirector/PDMR Shareholding
16th May 20187:00 amRNSNotice of Capital Markets Days
9th May 20185:40 pmRNSResult of AGM
4th May 20184:27 pmRNSDirector/PDMR Shareholding
2nd May 201810:52 amRNSDirector/PDMR Shareholding
1st May 20186:00 pmRNSDirector/PDMR Shareholding
30th Apr 20185:48 pmRNSDirector/PDMR Shareholding
26th Apr 20183:24 pmRNSHolding(s) in Company
25th Apr 20184:50 pmRNSHolding(s) in Company
24th Apr 20183:55 pmRNSHolding(s) in Company
24th Apr 201810:53 amRNSHolding(s) in Company
20th Apr 20184:09 pmRNSDirector/PDMR Shareholding
19th Apr 20184:32 pmRNSHolding(s) in Company
19th Apr 20187:00 amRNSQ1 Trading Update
5th Apr 201812:57 pmRNSHolding(s) in Company
5th Apr 201811:06 amRNSAnnual Financial Report
4th Apr 20186:01 pmRNSDirector/PDMR Shareholding
3rd Apr 20184:12 pmRNSBlock listing Interim Review
29th Mar 201811:55 amRNSTotal Voting Rights
27th Mar 20184:01 pmRNSHolding(s) in Company
27th Mar 201812:58 pmRNSAdditional Listing
8th Mar 20185:50 pmRNSDirector/PDMR Shareholding
1st Mar 20187:00 amRNSFinal Results
27th Dec 20177:00 amRNSDirector/PDMR Shareholding
20th Dec 20173:40 pmRNSDirector/PDMR Shareholding
22nd Nov 20174:30 pmRNSHolding(s) in Company
17th Nov 20177:00 amRNSIssue of new EUR400m bond
13th Nov 20174:35 pmRNSHolding(s) in Company
13th Nov 20177:00 amRNSPurchase of Vector Disease Acquisition LLC
7th Nov 20174:14 pmRNSHolding(s) in Company
6th Nov 20177:00 amRNSDirectorate Change
2nd Nov 20176:07 pmRNSHolding(s) in Company
1st Nov 20177:00 amRNSDirectorate Change
19th Oct 20177:00 amRNSQ3 Trading Update
2nd Oct 20173:26 pmRNSBlock listing Interim Review
21st Sep 20177:00 amRNSDirectorate Change
18th Sep 20177:00 amRNSDirectorate Change
22nd Aug 20173:34 pmRNSChange to Director's details
4th Aug 201711:57 amRNSDirector/PDMR Shareholding
31st Jul 20172:16 pmRNSDirector Declaration
27th Jul 20177:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.